Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from SELLAS Life Sciences Group ( (SLS) ).
On October 1, 2025, SELLAS Life Sciences Group, Inc. extended its sublease agreement with Times Square Tower Associates LLC for premises at Times Square Tower, New York. The sublease expiration date is now September 30, 2027, with no change in annual rent.
The most recent analyst rating on (SLS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on SELLAS Life Sciences Group stock, see the SLS Stock Forecast page.
Spark’s Take on SLS Stock
According to Spark, TipRanks’ AI Analyst, SLS is a Neutral.
SELLAS Life Sciences Group’s overall stock score is low due to significant financial challenges, including inconsistent revenue, negative profitability, and reliance on external financing. The technical analysis shows strong momentum, but overbought conditions pose near-term risks. Valuation metrics are concerning with a negative P/E ratio and no dividend yield, further impacting the stock’s attractiveness.
To see Spark’s full report on SLS stock, click here.
More about SELLAS Life Sciences Group
Average Trading Volume: 2,280,295
Technical Sentiment Signal: Hold
Current Market Cap: $180.1M
See more data about SLS stock on TipRanks’ Stock Analysis page.